Core Alternative Capital Sells 234 Shares of Danaher Co. (NYSE:DHR)

Core Alternative Capital decreased its holdings in Danaher Co. (NYSE:DHR) by 9.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,188 shares of the conglomerate’s stock after selling 234 shares during the period. Core Alternative Capital’s holdings in Danaher were worth $502,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. FMR LLC grew its position in shares of Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after purchasing an additional 3,217,631 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Danaher by 17.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after purchasing an additional 535,254 shares during the last quarter. International Assets Investment Management LLC grew its position in shares of Danaher by 40,196.5% in the third quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after purchasing an additional 428,897 shares during the last quarter. Montrusco Bolton Investments Inc. grew its position in shares of Danaher by 30.4% in the third quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after purchasing an additional 397,671 shares during the last quarter. Finally, Union Bancaire Privee UBP SA acquired a new position in shares of Danaher in the fourth quarter valued at approximately $74,551,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 1.6 %

Shares of NYSE:DHR opened at $203.42 on Tuesday. The firm has a market cap of $146.92 billion, a P/E ratio of 38.53, a P/E/G ratio of 2.68 and a beta of 0.83. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12-month low of $203.00 and a 12-month high of $281.70. The business has a fifty day simple moving average of $232.72 and a 200 day simple moving average of $251.61.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the prior year, the company posted $2.09 earnings per share. Analysts predict that Danaher Co. will post 7.67 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were issued a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.53%. Danaher’s payout ratio is currently 20.45%.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. JPMorgan Chase & Co. reduced their price target on Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Royal Bank of Canada reissued an “outperform” rating and set a $277.00 price target (down previously from $299.00) on shares of Danaher in a research report on Thursday, January 30th. Guggenheim assumed coverage on Danaher in a research report on Thursday, December 19th. They set a “buy” rating and a $275.00 price target on the stock. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a research report on Thursday, October 31st. Finally, Jefferies Financial Group cut their target price on Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a research note on Wednesday, January 29th. Seven research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $278.00.

Insider Activity

In other news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 11.10% of the stock is currently owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.